Zelira Therapeutics Ltd. announced the US launch of the Zelira Dermatology Business' first product line, RAF FIVETM through its dermatology subsidiary Ilera Derm LLC (Zelira Dermatology). The five-product RAF FIVETM line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads. The products include known skin-boosting ingredients hyaluronic acid, niacinamide, glycerin, thiotaine (derived from mushrooms), and peptides. The RAF FIVETM line is Zelira's first step into the acne medication market valued at more than US$11 billion worldwide. Available now in the United States at www.raffive.com, RAF FIVETM is the skin care line in the world to feature Zylorma®, a patent-pending acne fighting complex developed by Zelira and US board-certified cosmetic dermatologist Dr. Karyn Grossman. Zylorma® uses a proprietary formulation with CBD, salicylic acid and additional botanical compounds to fight bacteria and clogged pores associated with acne, and balance sebum production to help eliminate and prevent acne breakouts. The results from RAF FIVE'sTM 28-day self-assessment survey of 45 participants showed significant improvements in the individuals using RAF FIVETM treatments. Zelira also conducted a rigorous industry standard consumer use study for its RAF FIVETM franchise that showed improvement in all of the participants during the 28 day study. Results showed significant improvement as early as 7 days for some of the participants.